2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Biological Therapies, Transplantation, Gene Therapy, Biological Processes, Apoptosis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Immunology, Autoimmune Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, CML, Study Population, Human, Animal Model
PAPER

3126 TNFRSF1A targeting in chronic myeloid leukemia stem cells results in reduction in competitive fitness compared to normal stem cells following TKI treatment

Tyler Freeland, B.S., Mason Harris2, Gracie Jack3, Tiff Ricketts, PhD4, Alecia Alto, BS5, Harish Kumar, PhD6, Na Xie, PhD7, Ravi Bhatia, MD8
1 University of Alabama at Birmingham, Birmingham, Alabama, United States
2 University of Alabama at Birmingham, Birmingham, Alabama, United States
3 University of Alabama at Birmingham, Birmingham, Alabama, United States
4 University of Alabama at Birmingham, Birmingham, Alabama, United States
5 University of Alabama at Birmingham, Birmingham, Alabama, United States
6 University of Alabama at Birmingham, Birmingham, Alabama, United States
7 University of Alabama at Birmingham, Birmingham, Alabama, United States
8 University of Alabama at Birmingham, Birmingham, Alabama, United States

Chronic myeloid leukemia (CML) leukemia stem cells (LSCs) evade tyrosine kinase inhibitor (TKI) treatment and persist as a source of disease relapse after TKI cessation. However, the long-term retention of CML cells in patients maintaining treatment-free remission (TFR) suggests that recurrence not only requires LSC persistence but also depends on factors determining the competitive fitness of leukemic vs. non-leukemic hematopoietic stem cells (HSCs), restricting LSC outgrowth. Previous studies show that inhibition of TNFa (tumor necrosis factor alpha) signaling can enhance LSC targeting when combined with TKI. Our single cell transcriptomic analyses of CML patient bone marrow (BM) samples from time of TKI cessation revealed increased TNF signaling activity through TNFRSF1A (TNF receptor 1A) in the HSC compartment of patients who subsequently recurred vs. maintained TFR. We hypothesized that TNFRSF1A signaling supports LSC fitness during TKI treatment, and TNFRSF1A targeting can decrease LSC fitness relative to non-leukemic HSCs.

To study the effect of TNFRSF1A targeting on the competitive growth of CML LSC and normal HSC following TKI treatment, we generated CML mice lacking TNFRSF1A by crossing a TNFRSF1A -/- mouse model with SCL-tTA BCR-ABL mice. Withdrawal of tetracycline allowed BCR-ABL expression and CML induction. BM from these CML-induced mice (CD45.1.2) and WT BM (CD45.2) were then transplanted into sub-lethally irradiated host mice (CD45.1) to establish chimeric CML mice. Six weeks post-transplantation, aligning with the earliest signs of disease, we treated mice with or without Nilotinib for four weeks. Blood, spleen, and BM were analyzed for chimerism of mature (T cell, B cell, myeloid) and HSPC populations (LT-HSC, ST-HSC, MPP and LMPP).

BCR-ABL TNFRSF1A -/- mice developed CML with similar kinetics to control BCR-ABL mice. However, Transplantation with TNFRSF1A -/- CML BM led to a notable increase in CML chimerism and myeloid bias in BM, spleen and blood compared to transplantation of control CML cells. LSC chimerism was significantly increased in mice transplanted with untreated TNFRSF1A -/- CML cells compared to control CML cells (p = 0.0026, FC = 2.37), whereas bystander LT-HSC frequency was significantly reduced (p = 0.0034, FC = 0.106). TKI treatment did not significantly change LSC chimerism in mice transplanted with control CML cells, but markedly reduced LSC chimerism in mice receiving TNFRSF1A -/- CML cells  (p = 0.0231, FC = 0.615), accompanied by the expansion of non-leukemic LT-HSC (p = 0.0213, FC = 5.69). TKI treatment resulted in a similar reduction of CML ST-HSC, MPP and LMPP populations in mice engrafted with TNFRSF1A -/- cells with expansion of non-CML cells in all compartments. On the other hand. mice receiving non-leukemic TNFRSF1A -/- BM together with control CML BM did not show altered chimerism or TKI response compared to mice transplanted with wildtype non-leukemic BM and CML BM, indicating that TNFRSF1A effects on the completive growth of leukemic and non-leukemic HSC with and without TKI were related to TNFRSF1A signaling in leukemic HSC.

Our results support an important role for TNFRSF1A signaling in maintaining the competitive fitness of CML LSC relative to normal HSC in the setting of TKI treatment. Ongoing studies are focused on elucidating the downstream mechanisms by which TNFRSF1A regulates LSC and HSC quiescence, self-renewal and TKI sensitivity. Selective targeting of TNFRSF1A may represent a promising strategy to reduce the competitive fitness of TKI-treated CML LSC compared with non-leukemic HSC and enhance the possibility of TFR.

Tyler Freeland, B.S.: No relevant conflicts of interest to declare.